Integrated Immune Engineering for Poor Prognosis Cancers
综合免疫工程治疗预后不良的癌症
基本信息
- 批准号:10700921
- 负责人:
- 金额:$ 186.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-16 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAccountingAntitumor ResponseApoptosisAreaBenefits and RisksBiomedical EngineeringBiophysicsBloodCAR T cell therapyCancer ControlCancer PatientCancer PrognosisCellsChemicalsClinicalClinical TrialsCollaborationsComplexComputersCytoskeletonDevelopmentDiagnosisEconomicsEffectivenessEngineeringEnvironmentExplosionFailureGeneticGenetic EngineeringGenetically Engineered MouseGenome engineeringGlioblastomaGrowthHealth BenefitImageImmuneImmune responseImmune systemImmunocompetentImmunologicsImmunologistImmunooncologyImmunotherapeutic agentImmunotherapyIn VitroLiquid substanceMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of pancreasMeasuresMechanicsMicrofabricationModelingOncologyPancreatic Ductal AdenocarcinomaPatientsPhasePhysicsPlantsProcessPrognosisProliferatingRiskSignal TransductionSolid NeoplasmStreamSystemT-LymphocyteTechnologyTestingTherapy trialTimeTissuesTranslationsTumor-infiltrating immune cellsanti-tumor immune responsebiophysical modelcancer cellcancer therapycell motilityclinical riskcomputational platformcostcytotoxicengineered T cellsexhaustionhigh resolution imaginghigh riskimmune cell infiltrateimmunoengineeringimmunotherapy clinical trialsimprovedin vivolive cell microscopymodel developmentmodels and simulationnanoscaleoptical imagingoptimismpatient populationpharmacologicphysical sciencepre-clinical assessmentpre-clinical researchpreclinical developmentprogramsresponsesuccesstumortumor immunologytumor progression
项目摘要
ABSTRACT
A key limitation to effective immunotherapy is the physical access of immune cells to the cancer cells. We
propose to develop a multiscale tumor simulator to predict tumor dynamics based on immune and cancer
cell migration and net proliferation as measured quantitatively from live cell microscopy. The tumor
simulator will be developed by biomedical engineers working in close collaboration with immunologists and
genetic engineers who are developing immunotherapies for pancreatic ductal adenocarcinoma and
glioblastoma. The tumor simulator will be a computational platform that will help guide immunotherapy
development and so will evolve to become an immunotherapy simulator. In addition, we will integrate state-
of-the-art genome engineering and microenvironmental engineering to bring a full suite of engineering
approaches to bear on the simulator development. Together, the simulator will be used to make
quantitative, testable predictions that are then tested experimentally using pharmacological and genetic
perturbations. By iterative model development we will test our central hypothesis that immune cell proximity
is a major determinant of effective anti-tumoral immune response, and limiting to effective immunotherapy
of solid tumors. Altogether, our Program Project will develop a comprehensive biophysics-based simulator
to predict tumor progression and accelerate immunotherapy development.
摘要
有效免疫疗法的一个关键限制是免疫细胞对癌细胞的物理访问。我们
我建议开发一个多尺度肿瘤模拟器,以预测基于免疫和癌症的肿瘤动力学
如活细胞显微镜定量测量的细胞迁移和净增殖。肿瘤
模拟器将由生物医学工程师与免疫学家密切合作开发,
正在开发胰腺导管腺癌免疫疗法的基因工程师,
胶质母细胞瘤肿瘤模拟器将是一个计算平台,将有助于指导免疫治疗
开发,因此将演变为免疫治疗模拟器。此外,我们将整合国家-
最先进的基因组工程和微环境工程,
模拟器开发的方法。总之,模拟器将用于使
定量的,可测试的预测,然后使用药理学和遗传学实验测试
扰动通过迭代模型开发,我们将测试我们的中心假设,即免疫细胞接近
是有效抗肿瘤免疫应答的主要决定因素,并限制有效的免疫治疗
实体肿瘤的总而言之,我们的计划项目将开发一个全面的基于生物制药学的模拟器
预测肿瘤进展并加速免疫疗法的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID ANDREW LARGAESPADA其他文献
DAVID ANDREW LARGAESPADA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID ANDREW LARGAESPADA', 18)}}的其他基金
Integrated Immune Engineering for Poor Prognosis Cancers
综合免疫工程治疗预后不良的癌症
- 批准号:
10270392 - 财政年份:2021
- 资助金额:
$ 186.91万 - 项目类别:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
发现 NF1 周围神经鞘瘤进展的治疗靶点
- 批准号:
10439480 - 财政年份:2020
- 资助金额:
$ 186.91万 - 项目类别:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
发现 NF1 周围神经鞘瘤进展的治疗靶点
- 批准号:
10653687 - 财政年份:2020
- 资助金额:
$ 186.91万 - 项目类别:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
发现 NF1 周围神经鞘瘤进展的治疗靶点
- 批准号:
10247078 - 财政年份:2020
- 资助金额:
$ 186.91万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10488079 - 财政年份:2019
- 资助金额:
$ 186.91万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10465297 - 财政年份:2019
- 资助金额:
$ 186.91万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10023258 - 财政年份:2019
- 资助金额:
$ 186.91万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10662510 - 财政年份:2019
- 资助金额:
$ 186.91万 - 项目类别:
Center for Modeling Tumor Cell Migration Mechanics
肿瘤细胞迁移机制建模中心
- 批准号:
9753166 - 财政年份:2016
- 资助金额:
$ 186.91万 - 项目类别:
Center for Modeling Tumor Cell Migration Mechanics
肿瘤细胞迁移机制建模中心
- 批准号:
9901832 - 财政年份:2016
- 资助金额:
$ 186.91万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 186.91万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 186.91万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 186.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 186.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 186.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 186.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 186.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 186.91万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 186.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 186.91万 - 项目类别: